Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a

S100B belongs to a family of calcium-binding proteins implicated in intracellular and extracellular regulatory activities. This study of serum S100B in primary progressive multiple sclerosis (PPMS) is based on data obtained from a randomized, controlled trial of Interferon beta-1a in subjects with P...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of negative results in biomedicine 2004-10, Vol.3 (1), p.4-4, Article 4
Main Authors:	Lim, Ee Tuan, Petzold, Axel, Leary, Siobhan M, Altmann, Daniel R, Keir, Geoff, Thompson, Ed J, Miller, David H, Thompson, Alan J, Giovannoni, Gavin
Format:	Article
Language:	eng
Subjects:	Adult Case-Control Studies Female Humans Interferon beta-1a Interferon-beta - therapeutic use Magnetic Resonance Imaging Male Multiple Sclerosis, Chronic Progressive - blood Multiple Sclerosis, Chronic Progressive - drug therapy Nerve Growth Factors - blood Nerve Growth Factors - metabolism S100 Calcium Binding Protein beta Subunit S100 Proteins - blood S100 Proteins - metabolism
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	S100B belongs to a family of calcium-binding proteins implicated in intracellular and extracellular regulatory activities. This study of serum S100B in primary progressive multiple sclerosis (PPMS) is based on data obtained from a randomized, controlled trial of Interferon beta-1a in subjects with PPMS. The key questions were whether S100B levels were associated with either disability or MRI findings in primary progressive MS and whether Interferon beta-1a has an effect on their S100B levels. Serial serum S100B levels were measured using an ELISA method. The results demonstrated that serum S100B is not related to either disease progression or MRI findings in subjects with primary progressive MS given Interferon beta-1a. Furthermore there is no correlation between S100B levels and the primary and secondary outcome measures.
ISSN:	1477-5751 1477-5751